Understanding Mental Health Treatments at Greenbrook
This study is looking back at information from Greenbrook's patient records to understand how well different mental health treatments work. It's examining patients who received NeuroStar TMS (a non-invasive brain stimulation device) or Esketamine (a nasal spray for depression). The study aims to see how much people's clinical outcome scores improved from before treatment to 8 weeks after treatment. This study is open to males and females aged 5 to 100 years old, as long as their treatment date was in 2011 or later and their information is complete. The current recruitment status is unclear.
- Study design
- This is an observational study that will look at existing data from 12,000 patients. It is a retrospective analysis, meaning it uses information already collected during regular patient care.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint measures changes in clinical outcome scores from baseline to 8 weeks post-treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Eleanor Cole, PhD · STUDY_DIRECTOR · Neuronetics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- change in clinical outcome scores from baseline to post treatment8 weeks
real-world efficacy of NeuroStar TMS as compared to Esketamine in reducing patients' symptoms, reduction in clinical assessment score like PHQ-9